<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639507</url>
  </required_header>
  <id_info>
    <org_study_id>14-008884</org_study_id>
    <nct_id>NCT02639507</nct_id>
  </id_info>
  <brief_title>International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients</brief_title>
  <acronym>ICV-DME</acronym>
  <official_title>International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients - the ICV-DME Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the effectiveness of vitrectomy for the treatment&#xD;
      of diabetic macular edema. Diabetes is known to cause retinal blood vessels to leak, leading&#xD;
      to swelling of the central retina (macula), and decreased vision. Removing the vitreous gel&#xD;
      with vitrectomy surgery is known to decrease the swelling caused by diabetes. Diabetic&#xD;
      retinopathy is often treated with laser or injections of medicine in to the eye.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>average (mean) improvement in Best Corrected Visual Acuity (BCVA) as measured with Snellen visual acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes With Diabetic Retinopathy With Macular Edema</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients will have the following characteristics:&#xD;
&#xD;
          -  Background diabetic retinopathy.&#xD;
&#xD;
          -  Center involving macular edema with CST &gt; 325 µm as measured by SD-OCT.&#xD;
&#xD;
          -  Predominantly intact (80%) ELM and IS/OS lines within 500 µm of the fovea on both&#xD;
             horizontal and vertical SD-OCT scans.&#xD;
&#xD;
          -  Best corrected Snellen visual acuity from 20/40 to 20/280 inclusive&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, &gt; 18 years of age with type 1 or 2 diabetes mellitus diagnosed and&#xD;
             treated by an endocrinologist, internist or family medicine physician&#xD;
&#xD;
          -  Background diabetic retinopathy&#xD;
&#xD;
          -  DME with central subfield thickness (CST) &gt; 325 µm by Spectral Domain Optical&#xD;
             Coherence Tomography (SD-OCT)&#xD;
&#xD;
          -  HbA1c level of &lt; 10.0 mg/dl&#xD;
&#xD;
          -  Previous cataract surgery with implantation of a stable posterior chamber intraocular&#xD;
             lens or a phakic eye with 1+ (out of 4+ scale) or less lens opacification&#xD;
&#xD;
          -  Predominantly intact (80%) external limiting membrane (ELM) and photoreceptor&#xD;
             inner/outer segment (IS/OS) lines within 500 µm of the fovea on horizontal and&#xD;
             vertical SD-OCT scans&#xD;
&#xD;
          -  Best corrected Snellen visual acuity from 20/40 to 20/280 inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intraocular anti-vascular endothelial growth factor (VEGF) injection within the&#xD;
             previous 3 months&#xD;
&#xD;
          -  Systemic anti-VEGF or receptor tyrosine kinase inhibitor therapy within the previous 3&#xD;
             months&#xD;
&#xD;
          -  Intraocular corticosteroid injection within the previous 6 months&#xD;
&#xD;
          -  Peri-ocular corticosteroid injection within the previous 3 months&#xD;
&#xD;
          -  Vitreomacular traction on SD-OCT scan (epiretinal membrane is allowed)&#xD;
&#xD;
          -  Previous anterior or pars plana vitrectomy&#xD;
&#xD;
          -  Glaucoma (IOP of &gt; 21 mmHg or regular use of more than 2 IOP lowering drugs)&#xD;
&#xD;
          -  Previous trabeculectomy&#xD;
&#xD;
          -  Likelihood of needing intraocular surgery within 6 months&#xD;
&#xD;
          -  Hard exudates involving the fovea&#xD;
&#xD;
          -  Proliferative diabetic retinopathy with any evidence of retinal traction&#xD;
&#xD;
          -  Cataract of grade 2+ or greater.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W Stewart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2015</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael W. Stewart, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

